HOME >> BIOLOGY >> NEWS
Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms

HORSHAM, PA (April 3, 2000) -- Exisulind (Aptosyn™) and other selective apoptotic antineoplastic drugs (SAANDs) inhibit the growth of prostate cancer cells in two ways, said researchers from Columbia University and their collaborators at Cell Pathways, Inc. (Nasdaq: CLPA). First, they directly kill cancerous prostate cells by inducing apoptosis. Secondly, they decrease expression of the androgen receptor in the cancerous prostate cells, making them less responsive to the growth-promoting effects of androgens in their environment. The Columbia University scientists and their Cell Pathways' collaborators presented their preclinical findings on Sunday April 2, 2000 at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco.

The researchers also demonstrated in a prostate cancer cell line that exisulind (Aptosyn™) and two other SAANDs, CP461 and CP248, inhibited the cellular expression and secretion of prostate specific antigen (PSA) at the same concentrations that induced apoptosis in the cells.

Dr. Bernard Weinstein, the senior investigator of these studies and director of the Columbia University Comprehensive Cancer Center, emphasized that "because of their dual mechanism of action, these agents are also effective in prostate cancer cells that have become independent of androgens."

"These findings also support the usefulness of PSA assays for measuring the efficacy of SAANDs in clinical trials for prostate cancer therapy or chemoprevention, as they demonstrate that a reduction in PSA levels accurately reflects cell death and not merely a reduction in PSA production when these drugs are used," added Rifat Pamukcu, M.D., chief scientific officer and senior vice president of research at Cell Pathways, Inc.

"This laboratory research complements the findings of our clinical trial of exisulind (Aptosyn™) as a treatment for post-prostatectomy men at risk of prostate cancer recurre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2 3

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. New hydrothermal vents discovered as South Pacific Odyssey research begins
3. Posters highlight water, energy and other natural resource research
4. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
5. K-State, other universities to study how climate affects plant evolution
6. The search for a kinder, gentler chemotherapy
7. Green tea research leads to gum and other products
8. New survey reveals insights into unique relationship between mothers and pediatricians
9. Manatee population rising in some regions, likely stalled or declining in others
10. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
11. Another key for the p53 door

Post Your Comments:
(Date:2/19/2015)... , Feb .19, 2015 Research and Markets ... addition of the "Military Electro-Optical / Infrared ... Technology, by Platform - Forecast to 2020" ... military electro-optical/infrared systems market is expected to reach ... of 7.71%. This report segments the ...
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
(Date:3/3/2015)... Clara, California (PRWEB) March 03, 2015 ... development service company, has launched a new Life Science ... reagents for preclinical research. , The first products ... antibody isotype controls, and soon to be released in ... company will continue to expand their life science portfolio ...
(Date:3/3/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") ... Opinion on Biological Therapy , Dr. Michael Chopp ... at the Henry Ford Hospital in Detroit, ... has the capacity to promote CNS and peripheral nervous ... to neurological recovery in each case.  They pointed out ...
(Date:3/3/2015)... Liberty Corner, New Jersey (PRWEB) March 03, 2015 ... in NJ, has announced today that it has ... DE. Terms of the transaction were not ... engineering consulting services to the energy sector including ... gas, alternative energy, and fossil and nuclear power ...
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Gene Therapy - Technologies, ... , Gene therapy technologies are described ... cell therapy with genetically modified vectors. Gene therapy ... various routes of administration as well as targeted ...
Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3
Cached News: